Please login to the form below
brain
This page shows the latest brain news and features for those working in and with pharma, biotech and healthcare.
New data backs GeNeuro’s MS drug after Servier exit
in brain atrophy, during this 96-week extension phase. ... stage of the disease and represent irreversible damage to the brain.
Latest news
-
Biogen and Eisai drop Alzheimer’s drug elenbecestat
of Aβ peptides, which in turn would reduce amyloid plaque formations in the brain and slow the progression of Alzheimer’s.
-
Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder
Deborah Dunsire, CEO, Lundbeck. Dunsire said Alder is “an excellent strategic fit for Lundbeck’s focused expertise in brain diseases and organisational capabilities”.
-
J&J’s ponesimiod tops Aubagio in head-to-head MS trial
Ponesimod also did significantly better than Sanofi’s drug on fatigue scores, MRI assessments of the number of active lesions in the brain, and the time to confirmed disability accumulation (CDA),
-
Third strike for BMS’ Opdivo in brain cancer
Despite failing first endpoint, trial is set to continue. Bristol-Myers Squibb’s (BMS) immuno-oncology blockbuster Opdivo has failed a third straight clinical trial in the hard-to-treat brain ... One reason GBM is such a tough nut to crack is that it
-
Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation
The trial also demonstrated that capmatinib was able to tackle lesions that had travelled to the brain, with seven of 13 patients showing a response and in some cases showing the ... The phase 2 VISION study of the drug also produced a positive overall
More from news
Approximately 3 fully matching, plus 563 partially matching documents found.
Latest Intelligence
-
Detecting Alzheimer’s ahead of a cure
Not only can it predict Alzheimer’s early, but the blood test is possibly more effective than the current standard of detection, a PET brain scan, according to the researchers. ... According to the charity, AstronauTx was formed to develop new
-
A roadmap to the successful treatment of Alzheimer’s disease
plaques and oligomers formed by beta-amyloid occur outside the brain cells of people with Alzheimer’s. ... It has long been known that brain immune cells called microglia maintain a healthy brain environment by clearing debris, including misfolded
-
Where next in Alzheimer’s disease R&D?
Elsewhere, J&J is working with the University of Pennsylvania on gene therapies capable of triggering the production of antibodies in the brain. ... Read more: Brain power: fresh approaches to Alzheimer's drug discovery.
-
Brain power: fresh approaches to Alzheimer’s drug discovery
Alector has devoted the last five years to the development of novel therapeutics that harness the brain’s immune system to treat neurodegeneration, identifying over 40 immune system targets, progressing more ... of a protein called TDP-43 that builds
-
Rare Diseases Day
They are focusing on enabling access to data and patients to drive the creation of an evidence base, while also helping firms to access the best brains needed to create a
More from intelligence
Approximately 0 fully matching, plus 50 partially matching documents found.
Latest appointments
-
Asceneuron appoints chief medical officer
His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for
-
Polleo Pharma co-founders join Chronos Therapeutics
In particular, their experience as co-founders of Polleo will be invaluable as we advance our behavioural brain disease portfolio.”.
-
Dr Niall Murphy and Pierre Schwich join Pharnext
He is currently an adjunct full professor of UCLA's department of psychiatry and biobehavioural sciences and a member of the Brain Research Institute at the David Geffen School of Medicine ... at the RIKEN Brain Science Institute.
-
Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon
The firm focuses on brain health, memory and ageing and its lead product is an oral amyloid aggregation inhibitor that targets Alzheimer's disease.
-
Ovid Therapeutics adds member to scientific advisory board
Ovid is a privately-held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain.
More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest from PMHub
-
Changing healthcare, one film at a time
Studies have shown that content which resonates emotionally with an audience activates more regions of the brain.
-
PANDAS/PANS Awareness: A parent’s story
As PANDAS is an autoimmune disease that leads to inflammation in the basal ganglia region of the brain, the symptoms (including head shakes, OCD, ADHD and vocal tics), tend to reappear
-
Can you survive without the blue dot?
Or has the digital world has replaced our brain. Have we become totally incompetent?
-
Creative problem solving, solved
According to De Bono our brain operates in patterns. When new information comes in it needs to fit within what we know already.
-
How to stop your brain putting the brakes on your next big idea
Peter Impey, Managing Director, 90TEN Comunications. I love it when a plan comes together. I also love the process of putting one together – from diving into a brief and gathering insights, to formulating strategies and then, of course, finding
More from PMHub
Approximately 1 fully matching, plus 76 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior / Principal Medical Writers wanted - MedComms - Various U...
-
Excellent Remuneration Packages
-
Senior Medical Writer
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Editorial Assistants - Medical Communications agency - Cheshire
-
Excellent Remuneration Package
-
Senior Copywriter
-
Salary TBC
- Experienced / Senior Medical Writer - Excellent Progression Oppo...
-
Excellent Salary and Benefits on offer
- Senior Account Manager / Account Director - MedComms - London
-
Highly competitive salary &package
- Senior Medical Writer – Medical Communications – North West – In...
-
Excellent Remuneration Package
Subscribe to our email news alerts
- Leading AstraZeneca’s return to growth in Europe
- Novartis bags US okay for Lucentis follow-up Beovu in wet AMD
- GSK forms cell therapy R&D pact with star-studded biotech
- Bayer/J&J claim new FDA okay for clot drug Xarelto
- Allergan investors back AbbVie deal, but is a tax charge looming?
- Bayer opens AI-enabled drug discovery center in UK
- Spotlight interview: 15 minutes on PR in pharma
- Changing healthcare, one film at a time
- Faisal Ahmed joins healthcare comms agency Sudler London
- Red Consultancy appoints MD in its health division
- Takeda offloads select portfolio to Acino ahead of Shire takeover
- Wilmington Healthcare appoints new consultants
PMHub
Makara Health
Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...
Latest intelligence
- eyeforpharma Marketing and Customer Innovation Europe
- By Richard Springham...
- The Golden Goose
- Why it’s so hard for the US to curb runaway drug prices...
- What is changing in cardiovascular disease care?
- Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
Quick links
Infographics
